Truist Securities Maintains Buy on DexCom, Raises Price Target to $102

Truist Securities analyst Richard Newitter has reaffirmed a Buy rating on DexCom (NASDAQ: DXCM) and increased the price target from $93 to $102. This adjustment reflects a positive outlook for the company's performance in the market.